Form 4 for STLN Starling Oncology, Inc.
Accepted 2023-11-21 00:00:00 ET · period of report 2023-11-17 · accession 0001628280-23-039815 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-11-21 | 2023-11-17 | STLN | Hively Brad | Dir | S - Sale+OE | $2.24 | -25.0K | 697.1K | -3% | -$56.0K |
| D | 2023-11-21 | 2023-11-17 | STLN | Hively Brad | Dir | M - OptEx | $0.85 | +25.0K | 722.1K | +4% | +$21.2K |
| D | 2023-11-21 | 2023-11-17 | STLN | Hively Brad | Dir | M - OptEx | $0.00 | -25.0K | 1.75M | -1% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2023-11-17 | S | D | 25,000 | $2.24 | 697,065 | D | — | — | |
| 2 | Common | Common stock | 2023-11-17 | M | A | 25,000 | $0.85 | 722,065 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-11-17 | M | D | 25,000 | $0.00 | 1,745,431 | D | $0.85 · — to 2029-12-02 | 25,000 Common stock | (F1) These options vest monthly for 36 months following November 12, 2021, the date of the closing of the Business Combination. |